ClinicalTrials.gg
RecruitingNCT06585007MEDCAREUpdated Sep 5, 2024

Metastasis-directed Therapy in Oligoprogressive Castration-refractory Prostate Cancer

A Phase 3 interventional study of Radiotherapy and metastasectomy in Castration-resistant Prostate Cancer and Oligoprogressive, sponsored by Universitaire Ziekenhuizen KU Leuven. Recruiting at 1 site in Belgium. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-09-05.

Sponsored by Universitaire Ziekenhuizen KU Leuven · Phase 3, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Dec 2023, registered Apr 2024).
  • Started Dec 2023; still recruiting 2 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
246
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Prostatic Neoplasms by Universitaire Ziekenhuizen KU Leuven — 8 open to participants now, 11 under way, 3 of them phase 3. Prostatic Neoplasms · Universitaire Ziekenhuizen KU Leuven.

Planned enrollment
3rd of 10
246 · median 131
Started
2023
the only one that year
Phase 3
2 of 12
2 open now
Primary completion
2029-01
later than 9 of 10 live
Registered
12th of 12
by date

Among the 12 studies in Prostatic Neoplasms by Universitaire Ziekenhuizen KU Leuven, this one is the 3rd largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2023, is one of 2 in phase 3, reaches primary completion later than 9 of the 10 other live ones, and was the 12th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

8 of the 12 studies in Prostatic Neoplasms by Universitaire Ziekenhuizen KU Leuven are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Prostatic Neoplasms by Universitaire Ziekenhuizen KU Leuven, or all of them as a file.
02

Study summary

Evaluation of the impact of metastasis-directed therapy in patients with castration-refractory prostate cancer and a maximum of 5 progressive lesions.

Read the detailed description

MEDCARE phase 3 trial is approved by the central Ethics committee. It is a multicentric, randomized, prospective, open-label, two-arm, phase III trial. The aim is to evaluate the impact of progression-directed therapy (PDT) in patients presenting with oligoprogressive mCRPC on overall survival (OS). The study will employ a 1:1 randomization between arm A and arm B. Patients will be stratified according to number of metastases (1 versus > 1), initial localization (local recurrence, N or M1a vs. M1b or M1c) and systemic therapy (patient type 1 vs. type 2, see below) (Fig 1). Randomization will be carried out after approval in the multidisciplinary tumour board were the standard-of-care treatment and kind of PDT (metastasectomy or SBRT) will be decided before randomization.

03

Conditions studied

  • Castration-resistant Prostate Cancer
  • Oligoprogressive

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants eligible for inclusion in this Trial must meet all the following criteria:

  • Written of the participant or their legally authorized representative has been obtained prior to any screening procedures.
  • Acinar adenocarcinoma (inclusive neuro-endocrine dedifferentiation).
  • Oligoprogressive disease on conventional imagine within a maximum of 6 weeks prior to randomisation defined as: a maximum of 3 extracranial progressive lesions (pre-existing lesions, the development of new lesions, or both) in any organ. Nodal (N1) disease should be measured in the short axis. Nodes more than 1.5 cm in the short axis are considered pathologic and measurable. Oligoprogression on bone scan is defined as the occurrence of maximal 3 new and/or progressive lesions. In case of not unambiguously, additional imaging such as diagnostic magnetic resonance imaging (MRI) or dedicated CT-scan should be performed. Visceral disease reported separately (lung, liver, adrenal, or CNS) and is considered measurable if an individual lesions is more than 1 cm longest dimension.

In case of locally persistent/recurrent disease, a diagnostic MRI of the prostate (bed) and/or of the site is recommended. There are two different mCRPC patient groups who are eligible for inclusion in the trial:

  1. Patients with oligoprogressive disease with pADT only as ongoing treatment (Type 1).
  2. Patients with oligoprogressive disease with pADT +/- systemic therapy. This is both the combination of pADT + ARTA as ongoing treatment or patients who had received docetaxel in the past (Type 2).

    • Castration- disease, defined as testosterone level \< 50 ng/dL.
    • Prior treatment of the primary tumor by radiotherapy or surgery. If the primary tumor has not been treated previously, this treatment is obligatory within the trial.
    • WHO performance 0-2
    • Age >= 18 years old
    • Absence of psychological, sociological, or geographical condition potentially hampering compliance with study protocol.
    • Patients must be presented at the multidisciplinary board meeting and the inclusion in the trial needs approval by this board.

Exclusion criteria

Exclusion Criteria:

  • Ductal adenocarcinoma and small-cell prostate cancer.
  • Serum testosterone level > 50 ng/ml.
  • Presence of poly-progressive disease, defined as more than 3 progressive lesions on conventional imaging or nodal and/or lesions on conventional imaging
  • Active other than prostate cancer that could potentially interfere with the interpretation of this trial.
  • Previous treatments (RT, surgery) or comorbidities rendering new treatment with SBRT impossible.
  • Spinal bone lesion that is highly symptomatic, neurologically threatening or at risk of fracture.
  • Patients already treated with radionuclides, cabazitaxel or PARP-inhibitors in the past.
  • Patients with progressive disease while receiving docetaxel.
  • Not able to understand the treatment protocol or sign .
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
246 participants (estimated)

Study arms

  • No intervention
    Standard of care therapy

    The standard of care can consist of surveillance (which means the continuation of the ongoing systemic treatment without any change) or initiation of NEST. The decision which option is considered must be decided at the multidisciplinary urologic oncology meeting (obligatory). MDT is not allowed in this arm. Options for NEST in this trial are abiraterone acetate, enzalutamide, apalutamide, darolutamide, olaparib, talazoparib, niraparib, cabazitaxel and docetaxel, radium-223, luthetium-177-PSMA.

  • Experimental
    Progression-directed therapy

    PDT (metastasectomy or SBRT) while continuing current systemic therapy: androgen-deprivation (ADT) alone, or ADT in combination with abiraterone acetate, enzalutamide, apalutamide and patients who had received docetaxel in the past. Patients under current treatment with docetaxel are not allowed, because the hypothesized interaction between docetaxel and radiotherapy concerning toxicity. In case of oligoprogression after PDT, repeated PDT to the new lesions is mandatory.

    Radiation: Radiotherapy · Procedure: metastasectomy

Interventions

  • RadiationRadiotherapy

    Progression-directed therapy (stereotactic body radiation therapy)

  • Proceduremetastasectomy

    Progression-directed therapy (metastasectomy)

This study also gives OlaparibStudies of OlaparibOlaparib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record., NiraparibStudies of NiraparibNiraparib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Overall Survival

    Overall Survival

    Time frame: will be calculated from the day of randomisation until death from any cause, wichever came first, assessed up to 5 years.

Secondary outcomes

  1. Quality of life scoring EORTC QLQ-C30

    Quality of life scoring using the EORTC QLQ-C30

    Time frame: Assessments are planned at baseline and during follow-up consultation at month 1, month 3, month 6, month 12 and month 24

  2. Quality of life scoring EORTC QLQ-PR25

    Quality of life scoring using the EORTC QLQ-PR25

    Time frame: Assessments are planned at baseline and during follow-up consultation at month 1, month 3, month 6, month 12 and month 24

  3. Quality of life scoring EQ-5D-5L

    Quality of life scoring using the EQ-5D-5L.

    Time frame: Assessments are planned at baseline and during follow-up consultation at month 1, month 3, month 6, month 12 and month 24

  4. Cancer Specific Survival

    Cancer Specific Survival

    Time frame: will be calculated from the day of randomisation until prostate cancer death, assessed up to 5 years.

  5. Radiographic progression free survival

    Radiographic progression free survival

    Time frame: will be calculated from the day of randomisation until the first day of progression (local, nodal or metastatic). Imaging is performed every 6 months during follow-up or at any time in case of PSA progression or symptoms, assessed up to 5 years.

  6. Progression-directed therapy induced acute or late toxicity scoring

    Acute and late toxicity as a result of radiotherapy will be scored using the Common Toxicity Criteria Version 5.0 and metastasectomy related toxicity will be scored using Clavien Dindo scoring system.

    Time frame: Toxicity will be scored every follow-up visit, assessed up to 5 years after progression-directed therapy.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Jan 2029, 61 months after the start.

Of 139 non-industry phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 99 months of starting (the median), counting those still running; a quarter within 57 and three quarters within 144. This study's planned 61 months is below that.

Counting every sponsor, half of 266 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2024
First posted
Sep 5, 2024
StartActual
Dec 19, 2023
Primary completionEst.
Jan 20, 2029
CompletionEst.
Jan 20, 2029
Last update
Sep 5, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06585007
Responsible party
Sponsor
First posted
Sep 5, 2024
Start date
Dec 19, 2023
Primary completion
Jan 20, 2029 (estimated)
Completion
Jan 20, 2029 (estimated)
Last update
Sep 5, 2024

Study contacts

Kato Rans, MD
Contact
kato.rans@uzleuven.be
003216347600
Gert De Meerleer, MD, PhD
Contact
gert.demeerleer@uzleuven.be
003216347600
Gert De Meerleer, MD, PhD
principal investigator · Universitaire Ziekenhuizen KU Leuven

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion